Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | DHFR | P00374 | 7/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.34 |
| ▸ | CCNC | P24863 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4691250 | 0.82 | MAP4K4 (0.42) | DHFR | |
| SCHEMBL4690844 | 0.82 | PLA2G10 (0.40) | DHFR | |
| SCHEMBL5795879 | 0.79 | PARP1 (0.38) | PARP1DHFRPTGER1PTGER4PTGER3 | |
| Trifluoroacetic Acid SCHEMBL4690959 | 0.79 | DHFR (0.41) | DHFR | |
| Trifluoroacetic Acid SCHEMBL5382553 | 0.79 | IKBKB (0.38) | DHFR | |
| SCHEMBL4691092 | 0.78 | DHFR (0.42) | DHFRPTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL4689031 | 0.78 | DHFR (0.58) | DHFR | |
| SCHEMBL4691056 | 0.77 | DHFR (0.48) | DHFR | |
| SCHEMBL4690991 | 0.77 | DHFR (0.43) | DHFR | |
| Trifluoroacetic Acid SCHEMBL4689849 | 0.76 | DHFR (0.46) | DHFRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1628979-B1 | DIAMINOPYRROLOQUINAZOLINES COMPOUNDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-03-19 | — | — | EP | claimed |
| CN-100344629-C | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | HOFFMANN LA ROCHE (CH) | 2007-10-24 | — | — | CN | claimed |
| US-7262297-B2 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-08-28 | — | — | US | claimed |
| CN-1791603-A | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | HOFFMANN LA ROCHE (CH) | 2006-06-21 | — | — | CN | claimed |
| US-20040235872-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | BERTHEL STEVEN JOSEPH (US) | 2004-11-25 | — | — | US | claimed |
| EP-1628979-B1 | DIAMINOPYRROLOQUINAZOLINES COMPOUNDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-03-19 | — | — | EP | disclosed |
| EP-1628979-B1 | DIAMINOPYRROLOQUINAZOLINES COMPOUNDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-03-19 | — | — | EP | disclosed |
| US-20070270445-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2007-11-22 | — | — | US | disclosed |
| US-20070270445-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2007-11-22 | — | — | US | disclosed |
| US-20070270445-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2007-11-22 | — | — | US | disclosed |
| CN-100344629-C | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | HOFFMANN LA ROCHE (CH) | 2007-10-24 | — | — | CN | disclosed |
| US-7262297-B2 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262297-B2 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262297-B2 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-08-28 | — | — | US | disclosed |
| CN-1791603-A | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | HOFFMANN LA ROCHE (CH) | 2006-06-21 | — | — | CN | disclosed |
| US-20040235872-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | BERTHEL STEVEN JOSEPH (US) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235872-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | PTPN5, PPP5C, PTP4A2 | PARP1 2602/4885DHFR 289/4885PTGER1 4589/4885 |
| US-20070270445-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | PTPN5, DUSP15, PPP5C | PARP1 2491/4885DHFR 339/4885PTGER1 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.